Related references
Note: Only part of the references are listed.Supplementation with phytoestrogens and insoluble fibers reduces intestinal carcinogenesis and restores ER-beta expression inApc-driven colorectal carcinogenesis
Cristina Luceri et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2020)
Acute changes in colonic PGE2 levels as a biomarker of efficacy after treatment of the Pirc (F344/NTac-Apc am1137) rat with celecoxib
Changhong Yun et al.
INFLAMMATION RESEARCH (2020)
Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs
Giulia Dell'Omo et al.
BRITISH JOURNAL OF CANCER (2019)
Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition
Praveen Rajendran et al.
CANCER RESEARCH (2019)
Vitamin D deficiency in the ApcPirc/+ rat does not exacerbate colonic tumorigenesis, while low dietary calcium might be protective
Amy A. Irving et al.
DISEASE MODELS & MECHANISMS (2018)
Heterocyclic Analogs of Sulforaphane Trigger DNA Damage and Impede DNA Repair in Colon Cancer Cells: Interplay of HATs and HDACs
Adaobi Okonkwo et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2018)
Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis Secondary Analysis of a Randomized Clinical Trial
N. Jewel Samadder et al.
JAMA ONCOLOGY (2018)
Evaluation of a Tumor-Targeting, Near-Infrared Fluorescent Peptide for Early Detection and Endoscopic Resection of Polyps in a Rat Model of Colorectal Cancer
Jade E. Jones et al.
MOLECULAR IMAGING (2018)
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia
Don A. Delker et al.
CANCER PREVENTION RESEARCH (2018)
Interaction between Wnt/beta-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of beta-catenin and RAS by targeting the Wnt/beta-catenin pathway
Woo-Jeong Jeong et al.
NPJ PRECISION ONCOLOGY (2018)
Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam
Furkan U. Ertem et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis
Zuyao Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease
Kosuke Kashiwabara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Global Cancer Incidence and Mortality Rates and Trends-An Update
Lindsey A. Torre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Reciprocal regulation of BMF and BIRC5 (Survivin) linked to Eomes overexpression in colorectal cancer
Rong Wang et al.
CANCER LETTERS (2016)
Genomic Landscape of Colorectal Mucosa and Adenomas
Ester Borras et al.
CANCER PREVENTION RESEARCH (2016)
Chemoprevention of familial adenomatous polyposis
Patrick M. Lynch
FAMILIAL CANCER (2016)
Development of a murine colonoscopic polypectomy model (with videos)
Furkan Ertem et al.
GASTROINTESTINAL ENDOSCOPY (2016)
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis A Randomized Clinical Trial
N. Jewel Samadder et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Sulindac, 3,3′-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis
Angelo Pietro Femia et al.
BMC CANCER (2015)
Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation
Naresh Devasari et al.
CARBOHYDRATE POLYMERS (2015)
High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer
Maureen E. Mork et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon
Praveen Rajendran et al.
CLINICAL EPIGENETICS (2015)
Molecular therapy of colorectal cancer: Progress and future directions
Wenhao Weng et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
Wei-Xiang Qi et al.
JOURNAL OF CHEMOTHERAPY (2015)
A novel COX-independent mechanism of sulindac sulfide involves cleavage of epithelial cell adhesion molecule protein
Jason L. Liggett et al.
EXPERIMENTAL CELL RESEARCH (2014)
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer
Ken-ichi Fujita et al.
LUNG CANCER (2014)
Mechanisms of RAS/β-catenin interactions
Eva Zeller et al.
ARCHIVES OF TOXICOLOGY (2013)
Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary Carcinogenesis
Ronald A. Lubet et al.
CANCER PREVENTION RESEARCH (2013)
Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer
Rong Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin Signaling
Nan Li et al.
MOLECULAR CANCER THERAPEUTICS (2013)
COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs
Evrim Gurpinar et al.
FRONTIERS IN ONCOLOGY (2013)
NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
Rong Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
β-catenin as a potential key target for tumor suppression
Yuejun Fu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model
Beatriz Pagan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
(-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells
Christine A. Larsen et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2010)
Molecular Alterations Associated with Sulindac-Resistant Colon Tumors in ApcMin/+ Mice
Emily J. Greenspan et al.
CANCER PREVENTION RESEARCH (2010)
Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
Alan P. Brown et al.
TOXICOLOGIC PATHOLOGY (2008)
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer
F. Gregory Buchanan et al.
CANCER RESEARCH (2007)
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
Bret Wacker et al.
CLINICAL CANCER RESEARCH (2007)
A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer
James M. Amos-Landgraf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
CA Townsley et al.
BRITISH JOURNAL OF CANCER (2006)
Prevention and management of duodenal polyps in familial adenomatous polyposis
LAA Brosens et al.
GUT (2005)
Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer
N Babbar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations
K Yang et al.
CARCINOGENESIS (2003)
Suppression of tumorigenesis in the Apcmin mouse:: down-regulation of β-catenin signaling by a combination of tea plus sulindac
GA Orner et al.
CARCINOGENESIS (2003)
Response of Apcmin and A33ΔNβ-cat mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
GA Orner et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2002)
Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study
M Cruz-Correa et al.
GASTROENTEROLOGY (2002)
Post-initiation effects of chlorophyllin and indole-3-carbinol in rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-f]quinoline
MR Xu et al.
CARCINOGENESIS (2001)
Share Paper
